Recent events
Recent events tied to this brand in public sources.
Back to profile52 entries · Page 1 of 3
2026
Johnson & Johnson joins US Myeloma Network as first industry collaborator
Johnson & Johnson joined the US Myeloma Network as its first industry collaborator, supporting the initiative launched by the International Myeloma Foundation.
2026
International Myeloma Foundation launches U.S. trial network with Johnson & Johnson
The International Myeloma Foundation announced the US Myeloma Network, a U.S. clinical research network, with Johnson & Johnson as its first industry partner. The network is intended to bring trials to academic and community oncology settings.
2026
Johnson & Johnson reports Q3 2026 earnings above estimates and raises full-year guidance
Johnson & Johnson reported third-quarter 2026 revenue of $25.4 billion and adjusted earnings of $2.59 per share, both above analyst estimates, driven by strong Tremfya sales, while medical technology sales rose only 2.5% to $8.6 billion, weighed down by geopolitical issues including the Middle East conflict. The company raised its full-year sales forecast to about $101.2 billion at the midpoint and increased its adjusted earnings forecast midpoint to $11.10 per share.
2026
Johnson & Johnson CFO Joseph Wolk discusses Q3 results
Johnson & Johnson chief financial officer Joseph Wolk discussed the company's third-quarter results in a CNBC segment; the available source text is limited to the headline and provides no specific financial figures.
2022
Johnson & Johnson launches Cape Town global health discovery satellite center with H3D
Johnson & Johnson announced the launch of a Satellite Center for Global Health Discovery at the H3D Centre, University of Cape Town, in collaboration with H3D. The center will focus on antimicrobial resistance, particularly multidrug-resistant Gram-negative bacteria.
2022
West Virginia settles opioid trial claims with Janssen
West Virginia agreed to a $99 million settlement with Johnson & Johnson subsidiary Janssen, removing Janssen from the ongoing opioid trial. The state had alleged that the companies made marketing misrepresentations and omissions and failed to guard against drug diversion. Johnson & Johnson said the settlement was not an admission of liability or wrongdoing.
2022
West Virginia finalizes $99 million settlement with Janssen
West Virginia finalized a $99 million settlement with Johnson & Johnson subsidiary Janssen Pharmaceuticals over the company’s alleged role in perpetuating the state’s opioid crisis. The settlement is not an admission of liability or wrongdoing by Johnson & Johnson or Janssen.
2022
Johnson & Johnson sues over counterfeit HIV drugs
Johnson & Johnson filed a lawsuit against drug distributors and a pharmacy seeking to block sales of counterfeit versions of its HIV medicines. The company said some counterfeit bottles contained a different HIV drug from the one on the label.
2022
J&J sues to block counterfeit HIV drug sales
Johnson & Johnson filed a lawsuit seeking to stop distributors and a pharmacy from selling counterfeit versions of its HIV drugs.
2022
Johnson & Johnson recalls a batch of PDS II sutures over cracks
Johnson & Johnson International's European Logistics Centre initiated a level-three recall of PDS II absorbable sutures, model FZ318H, batch RBMHMX, after cracks were found at the needle-thread connection in some products. The recall concerned France and Belgium; the affected products were not imported or sold in China.
2022
Johnson & Johnson and Remix Therapeutics form RNA research alliance
Johnson & Johnson and Remix Therapeutics announced a multi-drug research alliance. Johnson & Johnson is paying $45 million in upfront payment and research funding; its Janssen subsidiary receives exclusive rights to three targets with applications in immunology and oncology.
2021
Johnson & Johnson announces plan to spin off consumer health business
Johnson & Johnson announced that it would spin off its consumer health business as a separately listed company. The article says the process was expected to take approximately 18 to 24 months; implementation details, the new company's name and its leadership team had not yet been announced.
2021
Microsoft and Johnson & Johnson announce deeper cooperation in China
Microsoft and Johnson & Johnson announced plans to deepen their cooperation in China, including applying digital technologies in healthcare, supply chains and factories.
2021
Watsons launches more than 1,600 Sustainable Choices products
Watsons launched more than 1,600 “Sustainable Choices” products in stores and online, in collaboration with global supplier partners.
2021
FDA authorizes Moderna and Johnson & Johnson COVID-19 boosters
The FDA authorized a third Moderna dose for seniors and other people at high risk, and said recipients of Johnson & Johnson's single-dose vaccine should receive a second dose at least two months after their first. The FDA also allowed eligible people to receive a booster from a different vaccine brand.
2021
LTL Management files for bankruptcy protection
LTL Management, a subsidiary created by Johnson & Johnson, filed for bankruptcy protection in North Carolina. Johnson & Johnson said it had transferred $2 billion in baby powder lawsuit settlement money to LTL. The filing comes amid lawsuits alleging that the company's talcum powder caused cancer; the source also reports that a large government-led study found no strong evidence linking talc powder with ovarian cancer.
2021
Lawsuit alleges Johnson & Johnson marketed talcum products to Black women despite alleged risks
The National Council of Negro Women filed a lawsuit on behalf of the council alleging that Johnson & Johnson marketed talcum powder products directly to Black women despite alleged cancer risks. The claims are allegations, not a stated court determination.
2021
National Council of Negro Women files talcum powder lawsuit against Johnson & Johnson
The National Council of Negro Women, represented by attorney Ben Crump and his team, filed a lawsuit alleging that Johnson & Johnson endangered people by marketing talcum powder products directly to Black women. The lawsuit alleges the company knew of talcum's dangers as early as the 1960s; the supplied source reports allegations, not a court finding.
2021
Johnson & Johnson raises 2021 revenue forecast
Johnson & Johnson raised its 2021 revenue estimates and forecast $2.5 billion in COVID-19 vaccine sales for the year.
2021
Consumers file class-action lawsuit over recalled sunscreens
Johanna Dominguez and Sharron Meijer filed a class-action lawsuit against Johnson & Johnson in the U.S. District Court for the Northern District of California over affected sunscreen products, seeking an injunction and damages on behalf of consumers.